Oral administration of prostaglandin E2 in the hypoplastic left heart syndrome.
Oral administration of prostaglandin E2 resulted in marked clinical and hemodynamic improvement in patients with hypoplastic left heart syndrome. A lessening of metabolic acidosis and an increase in blood pressure were evident. These results indicate that the ductus arteriosus was effectively dilated by oral prostaglandin E2 in patients with ductus-dependent systemic circulation, as in the case of ductus-dependent pulmonary circulation. Surgical risk will also be reduced by pretreatment with oral prostaglandin E2.
D000284:Administration, Oral; D015232:Dinoprostone; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006330:Heart Defects, Congenital / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011300:Preoperative Care; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000494:pharmacology; D011652:Pulmonary Circulation / Q000187:drug effects
D011458:Prostaglandins E; D015232:Dinoprostone